Clinical Trials Logo

Clinical Trial Summary

This is a multi-centre phase I/II trial with an initial dose finding phase for cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab for patients with relapsed or relapsed / refractory multiple myeloma (MM) that have had at least 1 prior line of therapy


Clinical Trial Description

This is a multi-centre phase I/II trial with an initial dose finding phase for cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab for patients with relapsed or relapsed / refractory MM that have had at least one prior line of therapy.

As this combination has not been given before, participants will be registered initially into a dose finding phase where dose limiting toxicities (DLTs) will be monitored during the first cycle in order to confirm the recommended dose schedule (RD) of cyclophosphamide with lenalidomide and fixed dose pembrolizumab. A modified toxicity probability interval (mTPI) approach has been taken for dose finding, to determine a safe dose schedule defined as the probability of dose limiting toxicity below an acceptable rate of 34%.

Once a RD is identified an expansion phase is planned to estimate the activity profile of the Key-CR combination at the RD. The trial will start at the highest dose schedule . Cohorts of 3 evaluable participants will sequentially be recruited to the trial until the RD has been identified or the trial stopped due to excessive toxicity at dose schedule -1. The dose schedule to be given to a subsequent cohort will be evaluated after all participants have been followed up for one cycle or experienced a DLT. The Safety Review Committee (SRC) will be presented with a complete safety report in addition to a set of predetermined dosing decisions, such that all relevant information available may be considered before deciding upon the next dose schedule to be allocated.

The mTPI is an adaptive Bayesian design specifying that the parameter for the probability that a patient experiences a DLT during the first cycle follows a separate distribution for each dose level. Each DLT probability is believed to be equally likely to take any value between 0 and 1 before any data is collected this represents a non-informative or flat prior. The posterior distribution from which escalation decisions are made is constructed by updating the prior distribution with observed data and represents our updated beliefs about the parameter after having seen the data. The decision to remain at the current dose schedule (S), escalate (E), or de-escalate (D) from the posterior distribution is determined by probability theory and two clinical criteria; the minimum DLT rate that if true would warrant escalation and the maximum DLT rate that if true would warrant dose de-escalation. The clinical interval is specified to be (0.2, 0.34) in this setting. Below 0.2 would represent under-dosing and warrant escalation, above 0.34, over-dosing and de-escalation and in the interval proper dosing and the decision to remain at the current dose level.

Participants will be registered to a dose schedule in cohorts of 3 evaluable participants and a decision regarding expansion or dose (de)escalation will be made once all patients have been followed up for the full DLT observation period (see below).

A minimum of 6 participants must be evaluated at a dose schedule for the dose schedule to be considered the RD. If dose schedule -1 or 0 meet the RD criterion but the dose schedule above has not been excluded, a further cohort of participants may be treated at the dose schedule above at discretion of the SRC. If dose schedule -1 is found to be unsafe the trial will terminate early without opening the expansion phase. The SRC may consider increasing the size of cohorts after 12 evaluable participants have been treated at a dose schedule without identifying the RD. Once the RD has been identified the trial will move into the expansion phase.

It is essential that the data for each participant is returned in a timely manner to allow the participants to be monitored for safety and dose limiting toxicities that could affect the safety of other participants. Data must be returned on time to allow a timely review of the trial by the Safety Review Committee to prevent a hold up in progressing the trial to the next phase or dose level, or to allow it to be stopped quickly in the event of an unforeseen issue occurring.

Dose Schedules - 28 days schedule Dose schedule 1 (starting dose) Pembrolizumab 200mg every 3 weeks, cyclophosphamide 500mg days 1&8, lenalidomide 25mg days 1-21 Dose schedule 0 Pembrolizumab 200mg every 3 weeks, cyclophosphamide 500mg day 1, lenalidomide 25mg days 1-21 Dose schedule -1 Pembrolizumab 200mg every 3 weeks, cyclophosphamide 500mg day 1, lenalidomide 15mg days 1-21 ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03191981
Study type Interventional
Source University of Leeds
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date August 1, 2017
Completion date August 1, 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06205823 - Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
Recruiting NCT04782687 - Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma Phase 2
Active, not recruiting NCT05889221 - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma N/A
Recruiting NCT03891914 - Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma Phase 3
Not yet recruiting NCT05944783 - Bioequivalence Studies of Dasatinib 100 mg Phase 4
Recruiting NCT04268199 - A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment Phase 2
Not yet recruiting NCT06133426 - Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients N/A
Completed NCT05887206 - Corneal Toxicity in Patients Treated by Belantamab Mafodotin
Completed NCT04065789 - Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients Phase 2
Active, not recruiting NCT03089411 - Collection of Additional Data Followed the Study IFM 2013-04 N/A
Completed NCT04436029 - Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Phase 2
Not yet recruiting NCT04364724 - CTFEA Myeloma Study
Recruiting NCT05932680 - Limited-duration Teclistamab Phase 2
Not yet recruiting NCT06418750 - Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study N/A
Completed NCT04236063 - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Terminated NCT04242121 - The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
Not yet recruiting NCT03607643 - A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Phase 1/Phase 2
Recruiting NCT05651932 - A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT06245629 - Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Recruiting NCT03992170 - Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive Phase 2